Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
Fuente:
Redalyc
Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Centro de investigaciones y Publicaciones Farmacéuticas
2006
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1876438278273499136 |
|---|---|
| author | Brian K. Irons |
| author_facet | Brian K. Irons |
| contents | Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications Brian K. Irons Tom Xu Krystal L. Edwards Medicina Cost Insulin Diabetes Glargine Exenatide Objective: To better understand exenatides role inthe treatment of type 2 diabetes, this analysisassessed its cost-effectiveness in comparison to anintermediate (NPH) and long-acting insulin(glargine). Exenatide is a recently approvedmedication for the treatment of type 2 diabetes foruse in addition to frequently used oral diabetesmedications.Methods: Two studies were identified by a Medlinesearch (1996-Oct 2005) that were similar in studyduration, baseline glycemic control, population size,and primary outcomes to appropriately assess thecost-effectiveness of either insulin in comparison toexenatide on both glycemic and weight control.Results: Both NPH and glargine appear to be morecost effective than exenatide with respect toglycemic control (incremental CE ratios -1,968 and -65,520 respectively). Exenatide appears to be morecost effective for reductions in body weight thaneither NPH (CE ratio 235) or glargine (CE ratio128).Conclusions Compared to intermediate and longactinginsulin therapies, exenatide does not appearto be as cost effective for the treatment of type 2diabetes. 2006 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69040305 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.3 Vol.4 |
| format | Artículo científico |
| id | redalyc_69040305 |
| institution | Redalyc |
| language | en |
| publishDate | 2006 |
| publisher | Centro de investigaciones y Publicaciones Farmacéuticas |
| spellingShingle | Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications Brian K. Irons Medicina Cost Insulin Diabetes Glargine Exenatide Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications Brian K. Irons Tom Xu Krystal L. Edwards Medicina Cost Insulin Diabetes Glargine Exenatide Objective: To better understand exenatides role inthe treatment of type 2 diabetes, this analysisassessed its cost-effectiveness in comparison to anintermediate (NPH) and long-acting insulin(glargine). Exenatide is a recently approvedmedication for the treatment of type 2 diabetes foruse in addition to frequently used oral diabetesmedications.Methods: Two studies were identified by a Medlinesearch (1996-Oct 2005) that were similar in studyduration, baseline glycemic control, population size,and primary outcomes to appropriately assess thecost-effectiveness of either insulin in comparison toexenatide on both glycemic and weight control.Results: Both NPH and glargine appear to be morecost effective than exenatide with respect toglycemic control (incremental CE ratios -1,968 and -65,520 respectively). Exenatide appears to be morecost effective for reductions in body weight thaneither NPH (CE ratio 235) or glargine (CE ratio128).Conclusions Compared to intermediate and longactinginsulin therapies, exenatide does not appearto be as cost effective for the treatment of type 2diabetes. 2006 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69040305 en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.3 Vol.4 |
| title | Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications |
| topic | Medicina Cost Insulin Diabetes Glargine Exenatide |
| url | https://www.redalyc.org/articulo.oa?id=69040305 |